Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4835281 | 0.84 | MAPK1 (0.34) | AOC3CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL1952297 | 0.77 | SMYD2 (0.31) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL5322844 | 0.70 | PTGS2 (0.31) | — | |
| SCHEMBL707090 | 0.69 | MAPK1 (0.34) | AOC3CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL15888456 | 0.68 | MAPK1 (0.37) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL79874 | 0.68 | MAPK1 (0.37) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| Hydroxyamine SCHEMBL9901947 | 0.67 | ALDH1A1 (0.35) | AOC3CYP3A4SMYD2 | |
| SCHEMBL704188 | 0.67 | MAPK1 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL20954476 | 0.66 | TAAR1 (0.34) | — | |
| SCHEMBL4863255 | 0.66 | IDO1 (0.42) | CYP3A4HTTSMN1; SMN2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404650-B2 | Methods of treating cancer with doxazolidine and prodrugs thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110135618-A1 | METHODS OF TREATING CANCER WITH DOXAZOLIDINE AND PRODRUGS THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135618-A1 | METHODS OF TREATING CANCER WITH DOXAZOLIDINE AND PRODRUGS THEREOF | DNPEP, PEPD, PREP | AOC3 1122/4885CYP3A4 293/4885HTT 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.